Sarika Ogale

1.6k total citations
74 papers, 1.2k citations indexed

About

Sarika Ogale is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, Sarika Ogale has authored 74 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 15 papers in Rheumatology. Recurrent topics in Sarika Ogale's work include Lung Cancer Treatments and Mutations (16 papers), Economic and Financial Impacts of Cancer (12 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Sarika Ogale is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Economic and Financial Impacts of Cancer (12 papers) and Lung Cancer Diagnosis and Treatment (11 papers). Sarika Ogale collaborates with scholars based in United States, Switzerland and United Kingdom. Sarika Ogale's co-authors include Barbara Segal, Paul Brunetta, Frederick B. Vivino, Philip C. Fox, Simon Bowman, Nandita Murukutla, Lachy McLean, Jennifer L. Beaumont, David Cella and Jin‐Shei Lai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

Sarika Ogale

68 papers receiving 1.1k citations

Peers

Countries citing papers authored by Sarika Ogale

Since Specialization

Citations

This map shows the geographic impact of Sarika Ogale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarika Ogale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarika Ogale more than expected).

Fields of papers citing papers by Sarika Ogale

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarika Ogale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarika Ogale. The network helps show where Sarika Ogale may publish in the future.

Co-authorship network of co-authors of Sarika Ogale

This figure shows the co-authorship network connecting the top 25 collaborators of Sarika Ogale. A scholar is included among the top collaborators of Sarika Ogale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarika Ogale. Sarika Ogale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network 2025 ·Journal of Hepatocellular Carcinoma ·David Cosgrove, (unknown), (unknown), Sairy Hernandez, Sarika Ogale, Sami Mahrus, (unknown), Thomas W. Wilson, Gregory Patton, Arturo Loaiza‐Bonilla, Amit G. Singal	3
2	Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database 2024 ·Cancers ·David E. Kaplan, (unknown), (unknown), Fan Mu, Sairy Hernandez, Sarika Ogale, Jiayang Li, (unknown), Lizheng Shi, Amit G. Singal	1
3	ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study. 2024 ·Journal of Clinical Oncology ·Ticiana Leal, (unknown), (unknown), Qing Zhang, (unknown), Daniel Sheinson, Sarika Ogale, Ilze Bāra, Katja Schulze, Jason Porter	1
4	Prognostic significance of real-world (RW) recurrence patterns after resection or ablation of early-stage hepatocellular carcinoma (HCC): Insights from the US Medicare population. 2024 ·Journal of Clinical Oncology ·Shishir K. Maithel, Rongrong Wang, Joanna Harton, Adam C. Yopp, Shimul A. Shah, Flavio G. Rocha, Sairy Hernandez, Spencer Cheng, Sarika Ogale, (unknown)	1
5	Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network. 2024 ·Journal of Clinical Oncology ·David Cosgrove, (unknown), (unknown), Sairy Hernandez, Sarika Ogale, Sami Mahrus, (unknown), Thomas W. Wilson, Gregory Patton, Arturo Loaiza‐Bonilla, Amit G. Singal	1
6	Prognostic Significance of Recurrence and Timing of Recurrence on Survival Among Patients with Early-Stage Hepatocellular Carcinoma in U.S. Clinical Practice 2024 ·Annals of Surgical Oncology ·Shishir K. Maithel, Rongrong Wang, Joanna Harton, Adam C. Yopp, Shimul A. Shah, Flavio G. Rocha, Sairy Hernandez, (unknown), Sarika Ogale, (unknown)	0
7	Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC 2023 ·JTO Clinical and Research Reports ·Jay M. Lee, (unknown), Rongrong Wang, Ann Johnson, Sarika Ogale, Matthew Kent, Janet Lee	4
8	EP07.04-26 Real-World Biomarker Testing and Treatment Patterns Identified Using Machine Learning in Early Non-small Cell Lung Cancer 2023 ·Journal of Thoracic Oncology ·(unknown), K. Schulze, (unknown), (unknown), Sarika Ogale, Ana Johnson, (unknown), Matthew H. Secrest, Aaron B. Cohen, Emily Castellanos, (unknown), Melissa Estévez, (unknown)	2
9	ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study 2023 ·Targeted Oncology ·(unknown), (unknown), (unknown), Chia-Wei Lin, Sarika Ogale, Debajyoti Datta, Atul J. Butte, Lyudmila Bazhenova, Vivek A. Rudrapatna	11
10	Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing 2021 ·JCO Oncology Practice ·Daniel Sheinson, William B. Wong, (unknown), Sarika Ogale, Cary P. Gross	25
11	Cost of cystectomy-related complications in patients with bladder cancer in the United States 2020 ·Current Medical Research and Opinion ·(unknown), Kathleen Wilson, (unknown), Darren Tayama, (unknown), Sarika Ogale	9
12	Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings 2017 ·Journal of Gastrointestinal Cancer ·Arthur C. Houts, Sarika Ogale, S. Yousuf Zafar, Joleen M. Hubbard, Sacha Satram‐Hoang, Nicolas Sommer, Mark S. Walker	5
13	Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy 2017 ·Clinical Colorectal Cancer ·Stephen S. Johnston, Kathleen Wilson, Helen Varker, (unknown), Paul Juneau, Ellen Riehle, Sacha Satram‐Hoang, Nicolas Sommer, Sarika Ogale	9
14	Second-line metastatic urothelial carcinoma treatment and survival in real-world patients in the US 2016 ·Annals of Oncology ·Sumanta K. Pal, Matt D. Galsky, (unknown), Sarika Ogale, M. Živković, Joe Leigh Simpson, Christina Louise Derleth, Guru Sonpavde	2
15	A real-world study of patterns of Bacillus Calmette-Guerin (BCG) use and associated adverse events (AEs) in non-muscle invasive bladder cancer (NMIBC) patients in the United States 2016 ·Annals of Oncology ·Kathleen Wilson, (unknown), Sacha Satram‐Hoang, (unknown), (unknown), Darren Tayama, Sarika Ogale	1
16	Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis 2014 ·Health and Quality of Life Outcomes ·Jeroen P. Jansen, (unknown), (unknown), Sarika Ogale	53
17	PMS46 Patient Trade-Offs Between Frequency and Duration of Biologic Treatments for Rheumatoid Arthritis 2012 ·Value in Health ·Christine Poulos, Brett Hauber, Juan Marcos González, Sarika Ogale, Adam Turpcu	1
18	Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study 2012 ·Lara D. Veeken ·(unknown), Gerd‐Rüdiger Burmester, Sarika Ogale, Jenny Devenport, Anil John, Paul Emery	86
19	Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study 2011 ·BMC Musculoskeletal Disorders ·Sarika Ogale, (unknown), Henry J. Henk	43
20	Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: Results from an analysis of data from a US claims database 2009 ·Clinical Therapeutics ·Elise M. Pelletier, Sarika Ogale, Elaine Yu, Paul Brunetta, Jay Garg	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact